Staar Surgical (STAA) Earnings Preview: What to Expect on October 30th
Investors will be closely watching Staar Surgical (STAA) as the company prepares to release its quarterly earnings report on Wednesday, October 30th, 2024. Analysts are anticipating an earnings per share (EPS) of $0.17. While earnings performance is important, investors often focus on the company’s guidance for the upcoming quarter as a key indicator of future performance.
Looking Back at Past Earnings
In the previous quarter, Staar Surgical missed EPS estimates by $0.09. Despite the miss, the company saw a significant 11.03% increase in its share price the following day. This suggests that investors may be more sensitive to positive guidance than to slight misses in earnings. Here’s a breakdown of Staar Surgical’s past earnings performance and the resulting share price changes:
| Quarter | EPS Estimate | EPS Actual | Price Change % |
|—|—|—|—|
| Q2 2024 | $0.24 | $0.15 | 11.0% |
| Q1 2024 | $0.04 | -$0.07 | -12.0% |
| Q4 2023 | $0.17 | $0.16 | 3.0% |
| Q3 2023 | $0.18 | $0.30 | -17.0% |
Analyst Sentiment and Insights
Understanding market expectations and sentiment is crucial for investors. Two analysts currently cover Staar Surgical, with a consensus rating of Buy. The average one-year price target sits at $42.5, representing a potential upside of 38.48%.
A Look at Industry Peers
It’s helpful to compare Staar Surgical to its peers to understand its relative market positioning and performance expectations. Here’s a comparison of analyst ratings and price targets for Establishment Labs Hldgs, RxSight, and Bioventus, three prominent players in the industry:
| Company | Consensus Rating | Average 1-Year Price Target | Potential Upside (%) |
|—|—|—|—|
| Establishment Labs Hldgs | Neutral | $55.6 | 81.17% |
| RxSight | Buy | $63.14 | 105.73% |
| Bioventus | Buy | $13.67 | 55.46% |
Key Financial Indicators
Staar Surgical stands out in terms of revenue growth and gross profit compared to its peers. However, it lags behind in return on equity. Here’s a summary of key metrics for all four companies:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|—|—|—|—|—|
| Staar Surgical | Buy | 7.26% | $78.41M | 1.84% |
| Establishment Labs Hldgs | Neutral | -9.15% | $28.94M | -33.71% |
| RxSight | Buy | 67.65% | $24.25M | -2.77% |
| Bioventus | Buy | 10.32% | $103.64M | -14.89% |
About Staar Surgical
Staar Surgical Co is a leading manufacturer of implantable lenses for the eye. The company designs, develops, manufactures, and sells lenses for both refractive surgery and cataract surgery. Their primary products are Implantable Collamer lenses (ICL) and intraocular lenses (IOL).
Key Financial Health Indicators
*
Market Capitalization:
Staar Surgical’s market capitalization is smaller than the industry average, which could be attributed to factors like growth expectations or operational capacity.*
Revenue Growth:
The company achieved an impressive revenue growth rate of 7.26% as of June 30, 2024. This reflects a substantial increase in top-line earnings. However, this growth rate falls behind the average for the Health Care sector.*
Net Margin:
Staar Surgical boasts a strong net margin of 7.45%, exceeding industry averages, demonstrating its profitability and effective cost management.*
Return on Equity (ROE):
With an ROE of 1.84%, the company demonstrates robust financial management and efficient use of shareholder equity capital.*
Return on Assets (ROA):
Staar Surgical’s ROA surpasses industry standards at 1.47%, highlighting efficient utilization of assets for optimal returns.*
Debt Management:
The company maintains a healthy debt-to-equity ratio of 0.09, indicating a sound financial structure.Staar Surgical’s earnings report is sure to be closely watched by investors, who will be looking for signs of continued growth and strong guidance for the future. To track all earnings releases for Staar Surgical, visit their earnings calendar on our site.
